相似文献
1
Promising drug targets and associated therapeutic interventions in Parkinson's disease.
Neural Regen Res. 2021 Sep;16(9):1730-1739. doi: 10.4103/1673-5374.306066.
2
Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
Brain. 2017 Sep 1;140(9):2460-2474. doi: 10.1093/brain/awx172.
3
Search for safer and potent natural inhibitors of Parkinson's disease.
Neurochem Int. 2021 Oct;149:105135. doi: 10.1016/j.neuint.2021.105135. Epub 2021 Jul 13.
4
Molecular understanding of the translational models and the therapeutic potential natural products of Parkinson's disease.
Biomed Pharmacother. 2022 Nov;155:113718. doi: 10.1016/j.biopha.2022.113718. Epub 2022 Sep 21.
5
Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
J Neurochem. 2016 Oct;139 Suppl 1:325-337. doi: 10.1111/jnc.13750. Epub 2016 Aug 30.
6
Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion and Delays Its Aggregation in rAAV-Based Rat Models of Parkinson's Disease.
J Neurosci. 2021 Sep 1;41(35):7479-7491. doi: 10.1523/JNEUROSCI.0476-21.2021. Epub 2021 Jul 21.
7
Molecular chaperones and Parkinson's disease.
Neurobiol Dis. 2021 Dec;160:105527. doi: 10.1016/j.nbd.2021.105527. Epub 2021 Oct 7.
8
Selected Natural and Synthetic Agents Effective against Parkinson's Disease with Diverse Mechanisms.
Curr Top Med Chem. 2022;22(3):199-208. doi: 10.2174/1568026621666211129141316.
9
Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease.
Mov Disord. 2021 Sep;36(9):2136-2143. doi: 10.1002/mds.28623. Epub 2021 May 7.
10
Management of Parkinson's disease in Ayurveda: Medicinal plants and adjuvant measures.
J Ethnopharmacol. 2017 Feb 2;197:46-51. doi: 10.1016/j.jep.2016.08.020. Epub 2016 Aug 17.
引用本文的文献
1
Targeting of the PI3 K/AKT/GSK3β Pathway in Parkinson's Disease: A Therapeutic Blueprint.
Mol Neurobiol. 2025 Jun 5. doi: 10.1007/s12035-025-05113-y.
2
Neuroprotective propensity of N-(5-chloro-2-hydroxyphenyl)-2-(morpholin-4-yl-methyl) benzamide, an inventive calcineurin inhibitor, in biological models of Parkinson's disease.
3 Biotech. 2025 Jun;15(6):149. doi: 10.1007/s13205-025-04314-5. Epub 2025 May 2.
3
Mitochondrial DNA editing: Key to the treatment of neurodegenerative diseases.
Genes Dis. 2024 Sep 21;12(4):101437. doi: 10.1016/j.gendis.2024.101437. eCollection 2025 Jul.
4
Therapeutic Role of Heterocyclic Compounds in Neurodegenerative Diseases: Insights from Alzheimer's and Parkinson's Diseases.
Neurol Int. 2025 Feb 7;17(2):26. doi: 10.3390/neurolint17020026.
5
Ameliorating effect of S-Allyl cysteine (Black Garlic) on 6-OHDA mediated neurotoxicity in SH-SY5Y cell line.
Toxicol Rep. 2024 Oct 9;13:101762. doi: 10.1016/j.toxrep.2024.101762. eCollection 2024 Dec.
6
An update on novel and emerging therapeutic targets in Parkinson's disease.
Metab Brain Dis. 2024 Aug;39(6):1213-1225. doi: 10.1007/s11011-024-01390-z. Epub 2024 Jul 27.
7
Transcriptome Study of rd1Mouse Brain and Association with Parkinson's Disease.
ACS Omega. 2024 Jun 6;9(24):25756-25765. doi: 10.1021/acsomega.3c09938. eCollection 2024 Jun 18.
8
Modeling neurodegenerative and neurodevelopmental disorders in the mushroom body.
Learn Mem. 2024 Jun 14;31(5). doi: 10.1101/lm.053816.123. Print 2024 May.
9
Research Progress of Bioactive Components in spp.
Molecules. 2024 Mar 7;29(6):1195. doi: 10.3390/molecules29061195.
10
Microglia in brain aging: An overview of recent basic science and clinical research developments.
J Biomed Res. 2024 Feb 26;38(2):122-136. doi: 10.7555/JBR.37.20220220.
本文引用的文献
1
Fibrillar α-synuclein toxicity depends on functional lysosomes.
J Biol Chem. 2020 Dec 18;295(51):17497-17513. doi: 10.1074/jbc.RA120.013428.
2
Effectiveness of the Iron Chelator CN128 in Mitigating the Formation of Dopamine Oxidation Products Associated with the Progression of Parkinson's Disease.
ACS Chem Neurosci. 2020 Nov 4;11(21):3646-3657. doi: 10.1021/acschemneuro.0c00557. Epub 2020 Oct 14.
3
Valeric Acid Protects Dopaminergic Neurons by Suppressing Oxidative Stress, Neuroinflammation and Modulating Autophagy Pathways.
Int J Mol Sci. 2020 Oct 16;21(20):7670. doi: 10.3390/ijms21207670.
4
Impaired autophagy in microglia aggravates dopaminergic neurodegeneration by regulating NLRP3 inflammasome activation in experimental models of Parkinson's disease.
Brain Behav Immun. 2021 Jan;91:324-338. doi: 10.1016/j.bbi.2020.10.010. Epub 2020 Oct 8.
5
α-Synuclein Overexpression Induces Lysosomal Dysfunction and Autophagy Impairment in Human Neuroblastoma SH-SY5Y.
Neurochem Res. 2020 Nov;45(11):2749-2761. doi: 10.1007/s11064-020-03126-8. Epub 2020 Sep 11.
6
The Impact of CRISPR-Cas9 on Age-related Disorders: From Pathology to Therapy.
Aging Dis. 2020 Jul 23;11(4):895-915. doi: 10.14336/AD.2019.0927. eCollection 2020 Jul.
7
Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain.
Expert Opin Ther Targets. 2020 Oct;24(10):1009-1028. doi: 10.1080/14728222.2020.1805435. Epub 2020 Aug 31.
8
Oxidative Stress and Neuroinflammation Potentiate Each Other to Promote Progression of Dopamine Neurodegeneration.
Oxid Med Cell Longev. 2020 Jul 3;2020:6137521. doi: 10.1155/2020/6137521. eCollection 2020.
9
Ghrelin protects dopaminergic neurons against MPTP neurotoxicity through promoting autophagy and inhibiting endoplasmic reticulum mediated apoptosis.
Brain Res. 2020 Nov 1;1746:147023. doi: 10.1016/j.brainres.2020.147023. Epub 2020 Jul 22.
10
Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies.
Pharmacol Rep. 2020 Oct;72(5):1195-1217. doi: 10.1007/s43440-020-00120-3. Epub 2020 Jul 22.
Zotero 插件